Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients

Obesity Research

Volumn 10, Issue 10, 2002, Pages 1008-1015

  Carey, David G ^a,e   Cowin, Gary J ^b   Galloway, Graham J ^b   Jones, Nigel P ^c   Richards, Jackie C ^c   Biswas, Nandita ^d   Doddrell, David M ^b  

^a Wesley Research Institute   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e NONE   (Australia)

Author keywords

Adipose tissue; Body fat distribution; Insulin sensitivity; Rosiglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHOLESTEROL; FATTY ACID; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIPOPROTEIN; ROSIGLITAZONE; THIAZOLE DERIVATIVE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BLOOD; BODY COMPOSITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIVER; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; RADIODENSITOMETRY; RANDOMIZED CONTROLLED TRIAL;

ADIPOSE TISSUE; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY COMPOSITION; CHOLESTEROL; DENSITOMETRY, X-RAY; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOPROTEINS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; THIAZOLES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0036776903     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2002.137     Document Type: Article

References (40)

1. Smith SA. Peroxisomal proliferator activated receptors (PPARs): molecular targets for hypolipidaemic agents and insulin sensitizers. Pharmacol Rev Commun. 1996;8:57-64.
2. Després JP, Moorjani S, Ferland M, et al. Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis. 1989;9: 203-10.
3. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care. 1991;14:1132-43.
4. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000;49:749-58.
5. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet. 1999;353:1634-6.
6. Marks SJ, Moore NR, Ryley NG, et al. Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. Int J Obes Relat Metab Disord. 1997;21:274-9.
7. Carey DG. Abdominal obesity. Curr Opin Lipidol. 1998;9: 35-40.
8. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor gamma have depotspecific effects on human preadipocyte differentiation. J Clin Invest. 1997;100:3149-53.
9. Edwards PA. Fatty livers and reduced adipose tissue, who wants it? J Clin Invest. 1996;98:1506-7.
10. Buckingham RE, Toseland CN, Campbell S, Draper N, Clarke K. Rosiglitazone reduces hepatic fat content. Diabetologia. 2000;43:A150.
11. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism. 1997;46:935-42.
12. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-23.
13. Abate N. Insulin resistance and obesity. The role of fat distribution pattern. Diabetes Care. 1996;19:292-4.
14. Abate N, Burns D, Peshock RM, Garg A, Grundy SM. Estimation of adipose tissue mass by magnetic resonance imaging: validation against dissection in human cadavers. J Lipid Res. 1994;35:1490-6.
15. Ross R, Fortier L, Hudson R. Separate associations between visceral and subcutaneous adipose tissue distribution, insulin and glucose levels in obese women. Diabetes Care. 1996;19: 1404-11.
16. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 1995;96: 88-98.
17. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45:633-8.
18. Gronemeyer S, Steen RG, Kauffman WM, Reddick WE, Glass JO. Fast adipose tissue (FAT) assessments by MRI. Magn Reson Imaging. 2000;18:815-8.
19. Ross R, Shaw KD, Rissanen J, Martel Y, de Guise J, Avruch L. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships. Am J Clin Nutr. 1994;59:1277-85.
20. Chowdhury B, Sjöström L, Alpsten M, Kostanty J, Kvist H, Lofgren R. A multicompartment body composition technique based on computerized tomography. Int J Obes Relat Metab Disord. 1994;18:219-34.
21. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging. 1994;12:487-95.
22. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999;276:E977-89.
23. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia. 2001;44:2210-19.
24. Matthews DR, Bakst A, Weston WM, Hemyari P. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes [Abstract]. Diabetologia. 1999;42(Suppl 1):858.
25. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86: 280-8.
26. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:308-15.
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352: 837-53.
28. Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999;22:908-12.
29. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998;101:1354-61.
30. Toseland CD, Campbell S, Francis I, Bugelski PJ, Mehdi N. Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat. Diabetes Obes Metab. 2001;3:163-70.
31. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazo lidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999;22:288-93.
32. Miyakawi Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes [Abstract]. Diabetes Res Clin Pract. 2000;50(Suppl 1):301.
33. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513-7.
34. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord. 1995;19: 846-50.
35. Goto T, Onuma T, Takebe K, Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord. 1995;19:841-5.
36. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes. 1994;43:1203-10.
37. Hockings P, Changhai K, Saeed N, et al. Rosiglitazone rapidly reverses hepatic steatosis. Diabetes. 2001;50(Suppl 2):1552.
38. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002;32(Suppl 3):24-34.
39. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-5.
40. Yang W-S, Jeng C-Y, Wu T-J, et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25:376-80.